{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:15:27Z","timestamp":1760746527921,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Biotechnology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.copbio.2016.03.007","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T22:01:19Z","timestamp":1462312879000},"page":"147-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A shot at AIDS"],"prefix":"10.1016","volume":"42","author":[{"given":"Wayne C","family":"Koff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.copbio.2016.03.007_bib0195","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.copbio.2016.03.007_bib0200","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.copbio.2016.03.007_bib0205","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.copbio.2016.03.007_bib0210","doi-asserted-by":"crossref","first-page":"e11068","DOI":"10.1371\/journal.pone.0011068","article-title":"Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco","volume":"5","author":"Das","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.copbio.2016.03.007_bib0215","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","author":"Lundgren","year":"2015","journal-title":"N Engl J Med"},{"year":"2015","author":"World Health Organization","series-title":"Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV","key":"10.1016\/j.copbio.2016.03.007_bib0220"},{"key":"10.1016\/j.copbio.2016.03.007_bib0225","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.copbio.2016.03.007_bib0230","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.copbio.2016.03.007_bib0235","first-page":"2083","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya","year":"2013","journal-title":"N Engl J Med"},{"year":"2015","author":"UNAIDS 2015","series-title":"AIDS by the Numbers","key":"10.1016\/j.copbio.2016.03.007_bib0240"},{"key":"10.1016\/j.copbio.2016.03.007_bib0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146387","article-title":"Exploring the potential health impact and cost-effectiveness of AIDS vaccine within a comprehensive HIV\/AIDS response in low- and middle-income countries","author":"Harmon","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.copbio.2016.03.007_bib0250","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1084\/jem.20072681","article-title":"The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?","volume":"205","author":"Sekaly","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.copbio.2016.03.007_bib0255","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.copbio.2016.03.007_bib0260","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1473-3099(12)70088-9","article-title":"Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B\/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144","volume":"12","author":"Merlin","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.copbio.2016.03.007_bib0265","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vacc Immunol"},{"key":"10.1016\/j.copbio.2016.03.007_bib0270","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.copbio.2016.03.007_bib0275","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/COH.0000000000000152","article-title":"Animal models in HIV prevention and therapy","volume":"10","author":"Hessell","year":"2015","journal-title":"Curr Opin HIV\/AIDS"},{"key":"10.1016\/j.copbio.2016.03.007_bib0280","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1241144","article-title":"Antibodies in HIV-1 vaccine development and therapy","volume":"341","author":"Klein","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.copbio.2016.03.007_bib0285","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12075","article-title":"HIV-1 neutralizing antibodies: understanding nature's pathways","volume":"254","author":"Mascola","year":"2013","journal-title":"Immunol Rev"},{"key":"10.1016\/j.copbio.2016.03.007_bib0290","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nbt.2197","article-title":"B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study","volume":"30","author":"Haynes","year":"2012","journal-title":"Nature Biotechnol"},{"key":"10.1016\/j.copbio.2016.03.007_bib0295","doi-asserted-by":"crossref","first-page":"17407","DOI":"10.7448\/IAS.15.2.17407","article-title":"The changing face of HIV vaccine research","volume":"15","author":"Kwong","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.copbio.2016.03.007_bib0300","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.copbio.2016.03.007_bib0305","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nature12966","article-title":"Proof of principle for epitope-focused vaccine design","volume":"507","author":"Correia","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.copbio.2016.03.007_sbref0310","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1126\/science.aac5894","article-title":"HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen","volume":"349","author":"Jardine","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.copbio.2016.03.007_bib0315","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1126\/science.1245627","article-title":"Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer","volume":"342","author":"Lyumkis","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.copbio.2016.03.007_bib0320","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1126\/science.1245625","article-title":"Crystal structure of a soluble cleaved HIV-1 envelope trimer","volume":"342","author":"Julien","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.copbio.2016.03.007_bib0325","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature13808","article-title":"Structure and immune recognition of trimeric pre-fusion HIV-1 Env","volume":"514","author":"PanceraF M.","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.copbio.2016.03.007_sbref0330","doi-asserted-by":"crossref","DOI":"10.1126\/science.aac4223","article-title":"HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers","author":"Sanders","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.copbio.2016.03.007_bib0335","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nm.1967","article-title":"Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys","volume":"8","author":"Johnson","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.copbio.2016.03.007_bib0340","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis","volume":"481","author":"Balazs","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.copbio.2016.03.007_sbref0345","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature14264","article-title":"AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges","volume":"519","author":"Gardner","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.copbio.2016.03.007_bib0350","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2013.09.061","article-title":"Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys","volume":"155","author":"Barouch","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.copbio.2016.03.007_bib0355","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nm.2089","article-title":"Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys","volume":"16","author":"Barouch","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.copbio.2016.03.007_bib0360","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature10766","article-title":"Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys","volume":"482","author":"Barouch","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.copbio.2016.03.007_bib0365","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2016.3","article-title":"Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized by protective responses in untreated infection","author":"Ondondo","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.copbio.2016.03.007_bib0370","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature12519","article-title":"Immune clearance of highly pathogenic SIV infection","volume":"502","author":"Hansen","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.copbio.2016.03.007_bib0375","doi-asserted-by":"crossref","DOI":"10.1126\/science.aac9475","article-title":"Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E","author":"Hansen","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.copbio.2016.03.007_sbref0380","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ni.3158","article-title":"Antibody response to envelope glycoproteins in HIV-1 infection","volume":"16","author":"Burton","year":"2015","journal-title":"Nat Immunol"}],"container-title":["Current Opinion in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0958166916300635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0958166916300635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T08:58:22Z","timestamp":1760691502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0958166916300635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":38,"alternative-id":["S0958166916300635"],"URL":"https:\/\/doi.org\/10.1016\/j.copbio.2016.03.007","relation":{},"ISSN":["0958-1669"],"issn-type":[{"type":"print","value":"0958-1669"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A shot at AIDS","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.copbio.2016.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}